TRIBE-2: FOLFOX or FOLFIRI With Bevacizumab in mCRC

FIRE-4.5: FOLFOXIRI plus either bevacizumab or cetuximab in mCRCПодробнее

TRIBE2: Latest data for patients with mCRCПодробнее

Second Line and Later Therapies - Metastatic Colorectal CancerПодробнее

1L FOLFOXIRI plus cetuximab or bevacizumab for RAS wild-type mCRCПодробнее

Dr. Cathy Eng on Bevacizumab Plus FOLFOXIRI for Patients With mCRCПодробнее

Frontline Therapy for Stage IV Right-Sided CRCПодробнее

mCRC: Combination Therapy and TestingПодробнее

Dr. Cremolini on FOLFOXIRI Plus Bevacizumab For Metastatic Colorectal CancerПодробнее

The Rationale for FOLFOX and Bevacizumab in mCRCПодробнее

FOLFOX and Avastin for metastatic colon cancerПодробнее

Second-Line and Salvage Treatment of Metastatic Colorectal CancerПодробнее

FIRE-4: evaluation of 1L efficacy of FOLFIRI/cetuximab in patients with RAS-WT mCRCПодробнее

Bevacizumab and cetuximab (plus chemo) have similar benefits in metastatic colorectal cancerПодробнее

DEEPER: m-FOLFOXIRI and cetuximab versus bevacizumab in mCRCПодробнее

FIRE-3 Study: Cetuximab Versus Bevacizumab in Metastatic Colorectal CancerПодробнее

mCRC: Considerations for Localized Therapy and MaintenanceПодробнее

DKN-01 with bevacizumab and chemotherapy in advanced CRCПодробнее

Understanding your treatment: Folfox-6 +/- Avastin chemotherapyПодробнее

Dr. O'Neil on Next Steps for Napabucasin With FOLFIRI and Bevacizumab in CRCПодробнее